Evidence map›Paper›PMID 35967402›Full record

ArticleFrontiers in immunology2022

Identification of CD8

Ning Ma, Huihui Liu, Yang Zhang, Wei Liu, Zeyin Liang, Qian Wang, Yuhua Sun, Lihong Wang, Yuan Li, Hanyun Ren and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 13 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ning MaDepartment of Hematology, Peking University First Hospital, Beijing, China.
Huihui LiuDepartment of Hematology, Peking University First Hospital, Beijing, China.
Yang ZhangDepartment of Hematology, Peking University First Hospital, Beijing, China.
Wei LiuDepartment of Hematology, Peking University First Hospital, Beijing, China.
Zeyin LiangDepartment of Hematology, Peking University First Hospital, Beijing, China.
Qian WangDepartment of Hematology, Peking University First Hospital, Beijing, China.
Yuhua SunDepartment of Hematology, Peking University First Hospital, Beijing, China.
Lihong WangDepartment of Hematology, Peking University First Hospital, Beijing, China.
Yuan LiDepartment of Hematology, Peking University First Hospital, Beijing, China.
Hanyun RenDepartment of Hematology, Peking University First Hospital, Beijing, China.
Yujun DongDepartment of Hematology, Peking University First Hospital, Beijing, China.
Peking University First Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a malignant plasma cell disorder affecting mainly the elderly population. Revolutionary progress in immunotherapy has been made recently, including monoclonal antibodies and chimeric antigen receptor T cell (CAR-T) therapies; however, the high relapse rate remains problematic. Therefore, combination therapies against different targets would be a reasonable strategy. In this study, we present a new X-chromosome encoded testis-cancer antigen (CTA) AKAP4 as a potential target for MM. AKAP4 is expressed in MM cell lines and MM primary malignant plasma cells. HLA-A*0201-restricted cytotoxic T lymphocytes (CTLs) induced by dendritic cells (DCs) transduced with an adenovirus vector encoding the full-length

Indexed as

A Kinase Anchor ProteinsCD8-Positive T-LymphocytesEpitopes, T-LymphocyteMultiple MyelomaAgedAnimalsCell Line, TumorHLA-A2 AntigenHumansLeukocytes, MononuclearMaleMicePeptidesAKAP4 protein, humanAkap4 protein, mouseA Kinase Anchor ProteinsEpitopes, T-LymphocyteHLA-A2 AntigenPeptidescancer-testis antigencytotoxic T lymphocytesdendritic cellmultiple myelomapeptide epitope

Identifiers

PMID35967402
PMCPMC9366082
OpenAlexW4288077142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.